The South Korea immunoglobulin market is expected to develop with a CAGR of 8.11% in terms of revenue during the estimated period, acquiring a revenue share of $936.18 million by 2028. The base year regarded for the market study is 2021, while the forecast years are from 2022 to 2028.

SOUTH KOREA IMMUNOGLOBULIN MARKET FORECAST 2022-2028

South Korea Immunoglobulin Market by Product (IGG, IGA, IGM, IGE, IGD) Market by Mode of Delivery (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Intramuscular Immunoglobulin) Market by Application (Hypogamma Globulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITB), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Other Applications) Market by Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Other Distribution Channels) Market by End-user (Hospitals & Clinics, Homecare)

Request free sample

Report Summary

Some of the top drivers proliferating the country’s market growth are the increasing geriatric population as well as the prevalence of different diseases and ailments due to weak immune systems.

To know more about this report, request a free sample copy

South Korea is witnessing a rapid increase in the geriatric population, a key factor expected to play an essential role in fueling the country’s demand for immunoglobulin. The elderly populace is at a greater risk of being diagnosed with immunodeficiency diseases, in addition to numerous other infections, as well. Multiple factors are accredited to altered cell-mediated immunity among the elderly, including thymic involution, reduced levels of thymic hormones, and an increasing number of immature T lymphocytes. In order to treat these conditions, the adoption of immunoglobulin products and therapies is likely to grow in South Korea over the upcoming years. Hence, these factors are expected to propel the market growth in the country during the forecast period.

The South Korea immunoglobulin market is mainly segmented into product, mode of delivery, application, distribution channel, and end-user. The application segment is further categorized into hypogamma globulinemia, primary immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, chronic inflammatory, demyelinating polyneuropathy, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, inflammatory myopathies, specific antibody deficiency, and other applications. Guillain-Barré syndrome is a critical and rare neurological disorder. The autoimmune condition impacts the peripheral nervous system, resulting in paralysis as well as weakness that is likely to last for months or years. It also produces an immune response in the body that can damage the nerve fiber, thus resulting in weakness and loss of sensation.

Various other applications of immunoglobulin include chronic lymphocytic leukemia, congenital AIDS, Kawasaki disease, and others. Kawasaki disease, also termed Kawasaki syndrome, is characterized as an acute febrile illness of unidentified etiology. As per a report published by the National Center for Biotechnology Information, the incidence of Kawasaki disease is recorded between 10 to 20 in 100,000 children across Canada and the United States and up to 50 to 250 in 100,000 in Japan.

Kawasaki disease is primarily observed in children below the age of 5. The disease’s complications entail coronary artery dilatations and aneurysms. The standard treatment includes intravenous immunoglobulin as well as aspirin, thus significantly minimizing the development of coronary artery abnormalities.

Some of the leading players operating in the South Korea immunoglobulin market are ABL Bio, Green Cross, Celltrion, etc.

Pfizer Inc, headquartered in the United States, is a multinational pharmaceutical and biotechnology corporation. It manufactures and develops medicines as well as vaccines for cardiology, immunology, oncology, endocrinology, and neurology. The company has a strong geographical presence with numerous locations spanning different countries and regions globally.

OCTAGAM Immune Globulin Intravenous (Human), the company’s product, is an immune globulin intravenous 5% liquid indicated for the treatment of primary humoral immunodeficiency.

Report Synopsis

Report Scope	Details
Market Forecast Years	2022-2028
Base Year	2021
Market Historical Years	2018-2021
Forecast Units	Revenue ($ Million)
Segments Analyzed	Product, Mode of Delivery, Application, Distribution Channel, End-User
Country Analyzed	South Korea
Companies Analyzed	ABL Bio, Celltrion, Green Cross, Orum

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- COUNTRY SNAPSHOT
- COUNTRY ANALYSIS
- KEY GROWTH ENABLERS
- KEY CHALLENGES
KEY ANALYTICS
- IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
  - BUYERS POWER
  - SUPPLIERS POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- PESTLE ANALYSIS
- KEY BUYING CRITERIA
  - SOURCE
  - APPLICATION
  - EPITOPE
  - VALIDATION

MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
  - MERGERS & ACQUISITIONS
  - PRODUCT LAUNCHES & DEVELOPMENTS
  - PARTNERSHIPS & AGREEMENTS
  - BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
  - ABL BIO
  - CELLTRION
  - GREEN CROSS
  - ORUM

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – IMMUNOGLOBULIN

TABLE 2: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 4: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 6: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 8: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 10: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2028 (IN $ MILLION)

TABLE 12: LIST OF MERGERS & ACQUISITIONS

TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 15: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: KEY BUYING CRITERIA

FIGURE 5: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 6: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 7: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 8: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 9: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 10: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 11: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 12: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2028 (IN $ MILLION)

FIGURE 13: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2028 (IN $ MILLION)

FIGURE 14: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2028 (IN $ MILLION)

FIGURE 15: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 16: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 17: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 19: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 20: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 21: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 22: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 23: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 24: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 25: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 26: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 27: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 31: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 32: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

SEGMENTATION

MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE